The US Food and Drug Administration will move into the process of drafting an implementable Quality Management Maturity rating system after a 2 November public endorsement of the concept from its Pharmaceutical Science & Clinical Pharmacology Advisory Committee.
The committee review amounted to the final stop on FDA’s process to build support at the conceptual level for the QMM proposal. FDA kicked off the 2022 campaign with a...